Frits van Rhee

List of Publications by Year
in descending order

265 papers	8,719 citations	71102 41 h-index	46799 89 g-index
267 all docs	267 docs citations	267 times ranked	7494 citing authors

#	Article	IF	Citations
1	The molecular classification of multiple myeloma. Blood, 2006, 108, 2020-2028.	1.4	997
2	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 2007, 109, 2276-2284.	1.4	831
3	International, evidence-based consensus diagnostic criteria for HHV-8â€"negative/idiopathic multicentric Castleman disease. Blood, 2017, 129, 1646-1657.	1.4	381
4	Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. Journal of Clinical Oncology, 2007, 25, 1121-1128.	1.6	369
5	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2014, 15, 966-974.	10.7	345
6	Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood, 2007, 109, 1692-1700.	1.4	328
7	HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood, 2014, 123, 2924-2933.	1.4	259
8	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	1.4	232
9	Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematology,the, 2016, 3, e163-e175.	4.6	213
10	Superior results of Total Therapy 3 (2003-33) in gene expression profilingâ€"defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood, 2010, 115, 4168-4173.	1.4	196
11	Siltuximab, a Novel Antiâ€"Interleukin-6 Monoclonal Antibody, for Castleman's Disease. Journal of Clinical Oncology, 2010, 28, 3701-3708.	1.6	195
12	Curing myeloma at last: defining criteria and providing the evidence. Blood, 2014, 124, 3043-3051.	1.4	194
13	Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood, 2013, 121, 1819-1823.	1.4	181
14	A Phase I, Open-Label Study of Siltuximab, an Antiâ€"IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clinical Cancer Research, 2013, 19, 3659-3670.	7.0	180
15	NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 2005, 105, 3939-3944.	1.4	173
16	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood, 2016, 128, 1735-1744.	1.4	170
17	Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 2009, 8, 2616-2624.	4.1	161
18	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 2006, 135, 158-164.	2.5	155

#	Article	IF	Citations
19	Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood, 2006, 107, 2633-2638.	1.4	129
20	Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clinical Advances in Hematology and Oncology, 2010, 8, 486-98.	0.3	112
21	Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood, 2010, 116, 1220-1227.	1.4	100
22	Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Clinical Cancer Research, 2007, 13, 7073-7079.	7.0	99
23	Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical Cancer Research, 2017, 23, 1981-1987.	7.0	97
24	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Advances, 2020, 4, 6039-6050.	5.2	94
25	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockadeâ€“refractory idiopathic multicentric Castleman disease. Journal of Clinical Investigation, 2019, 129, 4451-4463.	8.2	87
26	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clinical Cancer Research, 2015, 21, 4294-4304.	7.0	75
27	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood, 2018, 132, 59-66.	1.4	75
28	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Advances, 2020, 4, 422-431.	5.2	66
29	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 2007, 136, 393-399.	2.5	63
30	Plasma proteomics identifies a â€˜chemokine stormâ€™ in idiopathic multicentric Castleman disease. American Journal of Hematology, 2018, 93, 902-912.	4.1	63
31	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood, 2016, 128, 2919-2930.	1.4	57
32	The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma. Haematologica, 2017, 102, e364-e367.	3.5	57
33	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	12.8	54
34	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 30408-30419.	1.8	49
35	Treatment of Idiopathic Castleman Disease. Hematology/Oncology Clinics of North America, 2018, 32, 89-106.	2.2	49
36	First thalidomide clinical trial in multiple myeloma: a decade. Blood, 2008, 112, 1035-1038.	1.4	47

#	Article	IF	Citations
37	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1047-1053.	3.5	47
38	Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric <scp>Castleman</scp> disease. American Journal of Hematology, 2021, 96, 1241-1252.	4.1	47
39	Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 211-214.	0.4	46
40	Immunologic approaches for the treatment of multiple myeloma. Cancer Treatment Reviews, 2017, 55, 190-199.	7.7	46
41	Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels. PLoS ONE, 2013, 8, e54610.	2.5	44
42	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 2015, 100, 1214-1221.	3.5	44
43	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood, 2015, 125, 3756-3759.	1.4	41
44	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	12.8	41
45	The future of autologous stem cell transplantation in myeloma. Blood, 2014, 124, 328-333.	1.4	40
46	Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms. Journal of Clinical Oncology, 2010, 28, 3023-3027.	1.6	39
47	<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2422-2432.	7.0	37
48	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. American Journal of Hematology, 2017, 92, 739-745.	4.1	36
49	Predictors of response to antiâ€‹<scp>IL</scp>6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase <scp>II</scp> clinical trial data. British Journal of Haematology, 2019, 184, 232-241.	2.5	36
50	Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the Seventh Decade of Life. Journal of Molecular Diagnostics, 2014, 16, 68-74.	2.8	35
51	Infectious and immunological sequelae of daratumumab in multiple myeloma. British Journal of Haematology, 2019, 185, 187-189.	2.5	35
52	Daratumumab in highâ€risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British Journal of Haematology, 2020, 189, 67-71.	2.5	35
53	Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight, 2020, 5, .	5.0	35
54	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematology,the, 2020, 7, e209-e217.	4.6	34

#	Article	IF	Citations
55	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Medicine, 2020, 17, e1003323.	8.4	33
56	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical Cancer Research, 2018, 24, 2913-2919.	7.0	30
57	NY-ESO-1 immunotherapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 2037-2048.	1.3	29
58	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer Journal, 2020, 10, 70.	6.2	27
59	Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2014, 2014, 15.	2.7	26
60	CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood, 2014, 124, 2051-2060.	1.4	26
61	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica, 2017, 102, e313-e316.	3.5	26
62	Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia, 2018, 32, 2435-2444.	7.2	26
63	Daratumumab for POEMS Syndrome. Mayo Clinic Proceedings, 2018, 93, 542-544.	3.0	26
64	MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC Cancer, 2018, 18, 724.	2.6	26
65	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer Journal, 2019, 9, 62.	6.2	23
66	Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma. Blood, 2015, 126, 1777-1777.	1.4	23
67	Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS ONE, 2019, 14, e0218660.	2.5	22
68	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Advances, 2021, 5, 3445-3456.	5.2	22
69	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptorâ€"T Cell Therapy for Hematological Malignant Neoplasms. JAMA Network Open, 2022, 5, e228161.	5.9	22
70	Monitoring treatment response and disease progression in myeloma with circulating cellâ€free DNA. European Journal of Haematology, 2021, 106, 230-240.	2.2	21
71	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 108.	17.0	20
72	Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System. Clinical Cancer Research, 2007, 13, 1353-1355.	7.0	19

#	Article	IF	Citations
73	Patient-reported Outcomes for Multicentric Castlemanâ€™s Disease in a Randomized, Placebo-controlled Study of Siltuximab. Patient, 2015, 8, 207-216.	2.7	18
74	Mesenchymal stem cells gene signature in highâ€risk myeloma bone marrow linked to suppression of distinct IGFBP2â€expressing small adipocytes. British Journal of Haematology, 2019, 184, 578-593.	2.5	18
75	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American Journal of Hematology, 2020, 95, 1553-1561.	4.1	18
76	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Reports Medicine, 2020, 1, 100158.	6.5	18
77	Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.. Blood, 2004, 104, 77-77.	1.4	18
78	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
79	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	5.2	16
80	Siltuximab for multicentric Castleman disease. Expert Review of Hematology, 2014, 7, 545-557.	2.2	14
81	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances, 2022, 6, 808-817.	5.2	14
82	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical Cancer Research, 2017, 23, 2665-2672.	7.0	13
83	Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of <i>TP53</i>. Oncotarget, 2019, 10, 732-737.	1.8	13
84	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. Theranostics, 2019, 9, 4756-4763.	10.0	12
85	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. Blood, 2019, 134, 1887-1887.	1.4	12
86	Addition of Bortezomib (Velcadeâ„¢) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).. Blood, 2004, 104, 929-929.	1.4	12
87	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology, 2021, 17, 2499-2512.	2.4	11
88	TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. Journal of Clinical Investigation, 2021, 131, .	8.2	10
89	Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy. Blood, 2008, 112, 733-733.	1.4	10
90	Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC). Blood, 2011, 118, 298-298.	1.4	10

#	Article	IF	Citations
91	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of Bone and Mineral Research, 2017, 32, 1261-1266.	2.8	9
92	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	3.0	9
93	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers, 2021, 13, 4019.	3.7	9
94	Protective Effect of VELCADEÂ® on Thalidomide-Associated Deep Vein Thrombosis (DVT).. Blood, 2004, 104, 4914-4914.	1.4	8
95	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. Blood, 2016, 128, 4431-4431.	1.4	8
96	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. Blood, 2016, 128, 4516-4516.	1.4	8
97	Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma. Blood, 2011, 118, 2918-2918.	1.4	8
98	Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Research, 2022, 32, 1343-1354.	5.5	8
99	Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.. Blood, 2009, 114, 744-744.	1.4	7
100	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castlemanâ€™s Disease. Blood, 2013, 122, 505-505.	1.4	7
101	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. Blood, 2015, 126, 20-20.	1.4	7
102	Fulminant Onset of Acute Leukemia (FOAL) After Total Therapies (TT) for Multiple Myeloma (MM): Absence of MDS Pathological Criteria within 3 Months of Prior MM Follow-up. Blood, 2012, 120, 1458-1458.	1.4	7
103	Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Advances, 2022, 6, 4773-4781.	5.2	7
104	Light-chain MGUS: implications for clinical practice. Lancet, The, 2010, 375, 1670-1671.	13.7	6
105	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. Immunotherapy, 2016, 8, 367-384.	2.0	6
106	Castleman Disease. Hematology/Oncology Clinics of North America, 2018, 32, xiii-xiv.	2.2	6
107	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia, 2022, 36, 591-595.	7.2	6
108	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.. Blood, 2005, 106, 423-423.	1.4	6

#	Article	IF	Citations
109	Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis. Blood, 2011, 118, 884-884.	1.4	6
110	Prognostic Significance of DNA/Cig Flow Cytometry Assay in the â€˜eraâ€• of Novel Therapies in Multiple Myeloma (MM).. Blood, 2012, 120, 2918-2918.	1.4	6
111	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of Clinical Medicine, 2022, 11, 1640.	2.4	6
112	Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2854-2864.	7.0	6
113	Chimeric Antigen Receptor T-Cell Therapy in Multiple Myelomaâ€"Challenges and Potential Solutions. JAMA Oncology, 2022, 8, 823.	7.1	6
114	Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Diagnostic Pathology, 2018, 13, 15.	2.0	5
115	PHF19 inhibition as a therapeutic target in multiple myeloma. Current Research in Translational Medicine, 2021, 69, 103290.	1.8	5
116	Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare. Blood, 2019, 134, 1046-1046.	1.4	5
117	A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.. Blood, 2006, 108, 111-111.	1.4	5
118	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. Blood, 2014, 124, 3409-3409.	1.4	5
119	Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease. Blood, 2021, 138, 2696-2696.	1.4	5
120	Firstâ€•versus secondâ€generation Bruton tyrosine kinase inhibitors in WaldenstrÃ¶m's Macroglobulinemia: A systematic review and metaâ€analysis. American Journal of Hematology, 2022, 97, 942-950.	4.1	5
121	Race-Dependent Differences in Risk, Genomics, and Epsteinâ€"Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clinical Cancer Research, 2020, 26, 5814-5819.	7.0	4
122	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. British Journal of Haematology, 2021, 192, e28-e31.	2.5	4
123	<i>Ehrlichia</i>â€induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant. Transplant Infectious Disease, 2021, 23, e13621.	1.7	4
124	Bone remineralization of lytic lesions in multiple myeloma â€" The Arkansas experience. Bone, 2021, 146, 115876.	2.9	4
125	Persistent bone marrow minimal residual disease as a â€œhighâ€riskâ€• disease feature in multiple myeloma. American Journal of Hematology, 2021, 96, E341-E344.	4.1	4
126	Highâ€risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British Journal of Haematology, 2021, 195, 283-286.	2.5	4

#	Article	IF	Citations
127	EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. Blood, 2019, 134, 4569-4569.	1.4	4
128	Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients. Blood, 2008, 112, 667-667.	1.4	4
129	Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B. Blood, 2010, 116, 368-368.	1.4	4
130	Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4). Blood, 2014, 124, 1199-1199.	1.4	4
131	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. Blood, 2014, 124, 4775-4775.	1.4	4
132	HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review. Blood, 2014, 124, 4861-4861.	1.4	4
133	Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma. Blood, 2021, 138, 2802-2802.	1.4	4
134	Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies. Blood, 2021, 138, 566-566.	1.4	4
135	Idiopathic multicentric Castleman disease treated with siltuximab for 15â€‰years: a case report. Therapeutic Advances in Hematology, 2022, 13, 204062072210825.	2.5	4
136	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multiâ€institutional experience. American Journal of Hematology, 2022, 97, .	4.1	4
137	Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies. Blood, 2018, 132, 1882-1882.	1.4	3
138	Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma. Blood, 2018, 132, 408-408.	1.4	3
139	Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma. Blood, 2019, 134, 4383-4383.	1.4	3
140	Late Relapsing Multiple Myeloma â‰¥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. Blood, 2020, 136, 11-12.	1.4	3
141	Curing Multiple Myeloma (MM) with Total Therapy (TT). Blood, 2014, 124, 195-195.	1.4	3
142	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. Blood, 2014, 124, 3418-3418.	1.4	3
143	Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients. Blood, 2016, 128, 3304-3304.	1.4	3
144	Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain. Blood, 2019, 134, 1540-1540.	1.4	3

#	Article	IF	Citations
145	Engineering more efficacious antibody therapy for myeloma. Blood, 2014, 123, 3062-3063.	1.4	2
146	Transplantation for Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 227-250.	0.5	2
147	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, 106, 0-0.	3.5	2
148	The Mutational Landscape of Primary Plasma Cell Leukemia. Blood, 2018, 132, 114-114.	1.4	2
149	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. Blood, 2019, 134, 1845-1845.	1.4	2
150	Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. Blood, 2019, 134, 4333-4333.	1.4	2
151	Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients. Blood, 2012, 120, 579-579.	1.4	2
152	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. Blood, 2015, 126, 1806-1806.	1.4	2
153	Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines. Blood, 2015, 126, 1808-1808.	1.4	2
154	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. Blood, 2015, 126, 2979-2979.	1.4	2
155	The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition. Blood, 2016, 128, 1138-1138.	1.4	2
156	Myeloma-Derived Exosomes and Soluble Factors Suppress Natural Killer Cell Function. Blood, 2016, 128, 2066-2066.	1.4	2
157	Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment. Blood, 2016, 128, 3278-3278.	1.4	2
158	Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8514-8514.	1.6	2
159	Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival. Blood, 2013, 122, 1911-1911.	1.4	2
160	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. Blood, 2015, 126, 3181-3181.	1.4	2
161	Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression. Blood, 2016, 128, 115-115.	1.4	2
162	Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups. Blood, 2019, 134, 3309-3309.	1.4	2

#	Article	IF	Citations
163	NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma. Blood, 2021, 138, 2671-2671.	1.4	2
164	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. Blood, 2020, 136, 44-44.	1.4	2
165	The disease course of Castleman disease patients with fatal outcomes in the <scp>ACCELERATE</scp> registry. British Journal of Haematology, 2022, , .	2.5	2
166	Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?. Nature Clinical Practice Oncology, 2008, 5, 70-71.	4.3	1
167	A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 134-135.	3.0	1
168	Storming the Castle with TCP. Blood, 2019, 133, 1697-1698.	1.4	1
169	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, e20031-e20031.	1.6	1
170	Combinatorial treatment for unresectable unicentric Castleman disease. European Journal of Haematology, 2021, 107, 484-488.	2.2	1
171	Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. Blood, 2018, 132, 110-110.	1.4	1
172	Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center. Blood, 2018, 132, 3701-3701.	1.4	1
173	Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease. Blood, 2019, 134, 3599-3599.	1.4	1
174	Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).. Blood, 2005, 106, 3392-3392.	1.4	1
175	A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.. Blood, 2006, 108, 3393-3393.	1.4	1
176	Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5. Blood, 2012, 120, 193-193.	1.4	1
177	Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12â^¼23 Amplification. Blood, 2012, 120, 3983-3983.	1.4	1
178	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2014, 124, 2128-2128.	1.4	1
179	Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies. Blood, 2014, 124, 4464-4464.	1.4	1
180	Superior Restoration of Health with Siltuximab Among Multicentric Castlemanâ€™s Disease Patients When Measured By SF-36. Blood, 2014, 124, 4469-4469.	1.4	1

#	Article	IF	Citations
181	Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma. Blood, 2014, 124, 725-725.	1.4	1
182	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). Blood, 2015, 126, 1843-1843.	1.4	1
183	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. Blood, 2015, 126, 369-369.	1.4	1
184	The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM. Blood, 2015, 126, 372-372.	1.4	1
185	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. Blood, 2016, 128, 2065-2065.	1.4	1
186	Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC. Blood, 2016, 128, 3266-3266.	1.4	1
187	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. Blood, 2016, 128, 377-377.	1.4	1
188	The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.. Blood, 2005, 106, 1157-1157.	1.4	1
189	Bortezomib Down-Regulates HLA Class I and Enhances Natural Killer Cell Mediated Lysis of Myeloma.. Blood, 2006, 108, 3498-3498.	1.4	1
190	Recruitment in a randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in patients with multicentric Castlemanâ€™s disease.. Journal of Clinical Oncology, 2012, 30, TPS8117-TPS8117.	1.6	1
191	MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma. Blood, 2013, 122, 281-281.	1.4	1
192	ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis. Blood, 2014, 124, 2102-2102.	1.4	1
193	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. Blood, 2015, 126, 3182-3182.	1.4	1
194	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. Blood, 2016, 128, 117-117.	1.4	1
195	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. Blood, 2016, 128, 4416-4416.	1.4	1
196	Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance. Blood, 2018, 132, 4465-4465.	1.4	1
197	Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization. Blood, 2018, 132, 2415-2415.	1.4	1
198	Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches. Blood, 2018, 132, 1906-1906.	1.4	1

#	Article	IF	Citations
199	An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome. Blood, 2018, 132, 4489-4489.	1.4	1
200	Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Blood, 2021, 138, 4110-4110.	1.4	1
201	Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients. Cancers, 2021, 13, 6348.	3.7	1
202	Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis. EJHaem, 2022, 3, 748-753.	1.0	1
203	Nearly 70 years later: the continued unraveling of Castleman disease. Haematologica, 2023, 108, 7-8.	3.5	1
204	Reply to J.C. Regelink et al. Journal of Clinical Oncology, 2010, 28, e744-e745.	1.6	0
205	Optimizing the treatment of multiple myeloma. Nature Reviews Clinical Oncology, 2014, 11, 686-688.	27.6	0
206	NY-ESO-1 Specific T-Cells Are Spontaneously Present in High-Risk Myeloma and Kill Primary Myeloma Cells.. Blood, 2004, 104, 2454-2454.	1.4	0
207	KIR-LIGAND Mismatched Natural Killer Cells Effectively Kill Primary Myeloma and Myeloma Cell Lines.. Blood, 2004, 104, 2449-2449.	1.4	0
208	NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.. Blood, 2004, 104, 2464-2464.	1.4	0
209	Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.. Blood, 2005, 106, 1981-1981.	1.4	0
210	Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.. Blood, 2005, 106, 1152-1152.	1.4	0
211	Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs â€œDiscontinuousâ€•Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).. Blood, 2005, 106, 1153-1153.	1.4	0
212	Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.. Blood, 2007, 110, 5012-5012.	1.4	0
213	High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2, A Master Regulator of Mirna Maturation and B-Cell Development.. Blood, 2009, 114, 1804-1804.	1.4	0
214	Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM). Blood, 2010, 116, 1969-1969.	1.4	0
215	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.. Blood, 2010, 116, 1356-1356.	1.4	0
216	Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease,. Blood, 2011, 118, 3941-3941.	1.4	0

#	Article	IF	Citations
217	Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms. Blood, 2012, 120, 4020-4020.	1.4	0
218	Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.. Blood, 2012, 120, 2933-2933.	1.4	0
219	Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3). Blood, 2012, 120, 195-195.	1.4	0
220	Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups. Blood, 2012, 120, 1962-1962.	1.4	0
221	Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol. Blood, 2013, 122, 3137-3137.	1.4	0
222	Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity. Blood, 2013, 122, 5389-5389.	1.4	0
223	Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt. Blood, 2014, 124, 2078-2078.	1.4	0
224	Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study. Blood, 2014, 124, 2121-2121.	1.4	0
225	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. Blood, 2014, 124, 3407-3407.	1.4	0
226	Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study. Blood, 2014, 124, 5770-5770.	1.4	0
227	Treatment of Castleman Disease. , 2015, 12, .		0
228	Impact of total therapies on clinical outcome of myeloma stratified by risk and molecular subgroups.. Journal of Clinical Oncology, 2015, 33, 8586-8586.	1.6	0
229	Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts). Blood, 2015, 126, 1997-1997.	1.4	0
230	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. Blood, 2015, 126, 724-724.	1.4	0
231	Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma. Blood, 2015, 126, 2982-2982.	1.4	0
232	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. Blood, 2015, 126, 4173-4173.	1.4	0
233	Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma. Blood, 2015, 126, 2990-2990.	1.4	0
234	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 5395-5395.	1.4	0

#	Article	IF	Citations
235	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Blood, 2015, 126, 4193-4193.	1.4	0
236	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. Blood, 2016, 128, 2064-2064.	1.4	0
237	The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States. Blood, 2016, 128, 4438-4438.	1.4	0
238	Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior. Blood, 2018, 132, 4457-4457.	1.4	0
239	Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. Blood, 2018, 132, 4441-4441.	1.4	0
240	Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time. Blood, 2018, 132, 3168-3168.	1.4	0
241	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. Blood, 2018, 132, 4468-4468.	1.4	0
242	Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease. Blood, 2018, 132, 3716-3716.	1.4	0
243	Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria. Blood, 2018, 132, 4456-4456.	1.4	0
244	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. Blood, 2018, 132, 3185-3185.	1.4	0
245	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. Blood, 2018, 132, 4471-4471.	1.4	0
246	Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes. Blood, 2018, 132, 4448-4448.	1.4	0
247	Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma. Blood, 2018, 132, 3166-3166.	1.4	0
248	Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma. Blood, 2018, 132, 4466-4466.	1.4	0
249	Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors. Blood, 2018, 132, 1929-1929.	1.4	0
250	The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells. Blood, 2019, 134, 4412-4412.	1.4	0
251	The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma. Blood, 2019, 134, 508-508.	1.4	0
252	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. Blood, 2019, 134, 4379-4379.	1.4	0

#	Article	IF	Citations
253	The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells. Blood, 2019, 134, 4390-4390.	1.4	0
254	Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients. Blood, 2019, 134, 5638-5638.	1.4	0
255	Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. Blood, 2021, 138, 2713-2713.	1.4	0
256	N-Cadherin Stabilizes Î²-Catenin and Promotes Î²-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma. Blood, 2021, 138, 1572-1572.	1.4	0
257	Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome. Blood, 2021, 138, 1627-1627.	1.4	0
258	Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity. Blood, 2021, 138, 4004-4004.	1.4	0
259	Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma. Blood, 2020, 136, 2-2.	1.4	0
260	Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT. Blood, 2020, 136, 24-24.	1.4	0
261	CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction. Blood, 2020, 136, 21-21.	1.4	0
262	Con: allogeneic transplantation in multiple myeloma. Clinical Advances in Hematology and Oncology, 2006, 4, 391-4.	0.3	0
263	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American Journal of Hematology, 2022, 97, .	4.1	0
264	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, , .	3.5	0
265	Post hoc analysis of a long-term safety extension study: Responses to siltuximab in idiopathic multicentric Castleman disease patients receiving on-label dosing.. Journal of Clinical Oncology, 2022, 40, e19586-e19586.	1.6	0